---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-059570"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2021-12-07T23:59:59+00:00"
generated_at: "2026-06-28T03:12:22.187958+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# AbCellera appoints Andrew Lo as independent director; John Hamer resigns

## Summary
- Andrew W. Lo, Ph.D., appointed as independent director effective December 7, 2021.
- Lo will serve on Audit and Compensation Committees; he is an MIT professor and TIME 100 honoree.
- John Hamer, Ph.D., managing partner at DCVC Bio, resigned from the board effective immediately.
- Hamer had served on the board since 2018, including on Audit and Compensation Committees.
- CEO Carl Hansen thanked Hamer for his guidance and welcomed Lo for his financial/biomedical expertise.

## SEC filing metadata
- accession: 0001564590-21-059570
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2021-12-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000156459021059570/0001564590-21-059570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000156459021059570/abcl-8k_20211207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-059570
- JSON: https://secwatch.observer/filing/0001564590-21-059570.json
- Plain text: https://secwatch.observer/filing/0001564590-21-059570.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.